JP3813629B2 - バソプレッシン・アゴニストとしての縮合アゼピン - Google Patents
バソプレッシン・アゴニストとしての縮合アゼピン Download PDFInfo
- Publication number
- JP3813629B2 JP3813629B2 JP2005366100A JP2005366100A JP3813629B2 JP 3813629 B2 JP3813629 B2 JP 3813629B2 JP 2005366100 A JP2005366100 A JP 2005366100A JP 2005366100 A JP2005366100 A JP 2005366100A JP 3813629 B2 JP3813629 B2 JP 3813629B2
- Authority
- JP
- Japan
- Prior art keywords
- mmol
- group
- vasopressin
- compounds
- general formula
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 0 *C=C*C1=C(*)CNC(C=C*2)=C2*1 Chemical compound *C=C*C1=C(*)CNC(C=C*2)=C2*1 0.000 description 6
- NIDKGLRXRBFGEN-UHFFFAOYSA-N Cc(cc(cc1)C#N)c1C(O)=O Chemical compound Cc(cc(cc1)C#N)c1C(O)=O NIDKGLRXRBFGEN-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/10—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Cephalosporin Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Description
も低い経口生物学的利用能を有し、そしてこのパラメーターの中にいくつかの不確定要素がある。
発明は、改良された溶解度及び生物学的利用能を有する化合物を提供する。
本明細書に記載したとおり、本発明は、バソプレッシンの非ペプチド・アゴニストである化合物の系列(series)に関し、そしてそれはV2 レセプター・サブタイプについて選択的である。前記化合物は、一般式(1):
Aは以下の一般式(2)〜(7):
A1 、A4 、A7 、及びA10は、CH2 、O、及びNR8 から互いに独立して選ばれ;
A2 、A3 、A9 、A11、A13、A14、及びA15は、CH及びNから互いに独立して選ばれ;
A5 が共有結合であり、そしてA6 がSであるか、又はA5 がN=CHであり、そしてA6 が共有結合であるかのいずれかであり;
A8 及びA12はNH及びSから互いに独立して選ばれ;
A16及びA17は共にCH2 であるか、又はA16及びA17の一方がCH2 であり、そして他方がO、SOx 、及びNR8 から選ばれ、
V1 及びV2 は共にH、OMe若しくはFであるか、あるいはV1 及びV2 の一方がBr、Cl、F、OH、OMe、OBn、OPh、O−アシル、N3 、NH2 、NHBn若しくはNH−アシルであり、そして他方がHであるか、又はV1 及びV2 が一緒に=O、−O(CH2 )p O−若しくは−S(CH2 )p S−であり;
W1 はO又はSのいずれかであり;
X1 及びX2 は共にHであるか、又は一緒に=O若しくは=Sであり;
YはOR5 又はNR6 R7 であり;
ZはS又は−CH=CH−であり;
R1 、R2 、R3 、及びR4 はH、低級アルキル、低級アルキルオキシ、F、Cl、及びBrから選ばれ;
R5 はH及び低級アルキルから選ばれ;
R6 及びR7 はH及び低級アルキルから独立して選ばれるか、又は一緒に−(CH2 )n −であり;
R8 はH又は低級アルキルであり;
n=3,4,5又は6であり;
p=2又は3であり;そして
Xは0,1又は2である。}により説明される。
本発明は以下の一般式(1):
前記誘導体は前記のとおりではあるが、しかし縮合剤を必要とせずにアミンと反応する。
以下の略語を用いた。
Ac アセチル
AIBN アゾ−ビス−(イソブチロニトリル)
Bn ベンジル
BOC tert−ブチルオキシカルボニル
(BOC)2 O ジ−tert−ブチル・ジカルボネート
DMF ジメチルホルムアミド
Et エチル
EtOAc 酢酸エチル
IPA イソプロパノール
iPr イソプロピル
M.S. 質量分析
Me メチル
NBS N−ブロモサクシンイミド
pet.ether 石油エーテル、60〜80℃でボイルした画分
Ph フェニル
tBu tert−ブチル
THF テトラヒドロフラン
WSCDI 水溶性カルボジイミド
中間体の調製
断片A及びCに対応の試薬は、市販品であるか又は詳細なところを除いて具体的な実施例中に公告された手順に従い調製した。断片Bに対応の試薬を、以下に詳しく述べたとおり調製した。
4−(tert−ブチルオキシカルボニルアミノメチル)−3−クロロ安息香酸
四塩化炭素(50ml)中、3−クロロ−4−メチル安息香酸メチル(5.0g、27.1mmol)の溶液にNBS(5.8g、32.0mmol)及びAIBN(0.442g、2.70mmol)を加えた。その混合物を還流温度で18時間撹拌した。その混合物を室温まで冷却し、そして次に真空中で濃縮した。残渣をシリカによるフラッシュ・クロマトグラフィー(溶出液 EtOAc:pet.ether 0:100→5:95)により精製した;収量5.96g(84%)。
エタノール(170ml)中、アンモニアの飽和溶液に実施例A1の4−ブロモメチル−3−クロロ安息香酸メチル(5.5g、20.9mmol)を加えた。その混合物を室温で1時間撹拌し、そして次に真空中で濃縮した。残渣をジエチル・エーテルと一緒に粉砕し、そして得られた白色の結晶をろ過し、そしてさらなるジエチル・エーテルにより洗浄した。水(100ml)中、この固体の溶液にジオキサン(100ml)中、(BOC)2 O(5.0g、23.0mmol)の溶液、及び水(100ml)中、水酸化ナトリウム(1.86g、46.0mmol)を加えた。この混合物を室温で18時間撹拌し、そして次に真空中で濃縮した。残渣水溶液をクエン酸により酸性化し、そしてクロロホルム/IPAにより抽出した。有機層を水により洗浄し、MgSO4 により水分を除き、そして真空中で濃縮して白色の固体を得た;収量2.8g(67%)。
4−シアノ−3−メチル安息香酸
4−シアノ−2−メチル安息香酸
1−(2−メチル−4−(2,3,4,5−テトラヒドロ−1−ベンズアゼピン−1−イルカルボニル)ベンジルカルバモイル)−L−プロリン−N,N−ジメチルアミド
ジクロロメタン(50ml)中、2,3,4,5−テトラヒドロ−1H−ベンゾ〔b〕アゼピン(0.80g、5.44mmol)の溶液に4−シアノ−3−メチル安息香酸(0.96g、5.95mmol)、トリエチルアミン(0.60g、5.95mmol)、4−(ジメチルアミノ)ピリジン(0.73g、5.95mmol)、及びWSCDI(1.24g、6.48mmol)を加えた。その混合物を還流温度で18時間撹拌し、冷却し、そして真空中で蒸発させた。残渣をEtOAcと1M KHSO4 の間で分配した。その有機層を飽和重炭酸ナトリウム溶液及び食塩水により洗浄し、MgSO4 により水分を除去し、そして真空中で濃縮した。未精製物をシリカによるフラッシュ・クロマトグラフィー(溶出液 EtOAc:pet.ether 30:70)により精製した;収量1.10g(70%
)。
メタノール(50ml)中、実施例1Aのシアノベンズアゼピンの脱気した溶液(1.10g、3.79mmol)に濃塩酸(0.98ml、11.3mmol)及び10%炭素上パラジウム(0.80g)を加えた。水素ガスを室温で5時間その混合物に通気した。触媒をセライトのパッドを通してろ過することにより除去し、そしてろ液を蒸発させた;収量1.23g(98%)。
窒素雰囲気下、DMF(10ml)中、実施例1Bのアミンの溶液(0.10g、0.302mmol)にN,N−ジイソプロピルエチルアミン(43mg、0.332mmol)及びカルボニル・ジイミドアゼピン(0.074g、0.453mmol)を加えた。その混合物を室温で40分間撹拌した。DMF(1ml)中、プロリン−N,N−ジメチルアミドの溶液(0.107g、0.756mmol)を加えた。
その混合物を室温でさらに16時間撹拌した。溶媒を真空中で除去し、そして未精製物をシリカによるフラッシュ・クロマトグラフィー(溶出液メタノール=ジクロロメタン 5:95)により精製した;収量0.115g(82%)。
(4R)−4−ヒドロキシ−1−(2−メチル−4−(2,3,4,5−テトラヒドロ−1−ベンズアゼピン−1−イルカルボニル)ベンジル−カルバモイル)−L−プロリン−N,N−ジメチルアミド
ジクロロメタン(100ml)中、BOC−ヒドロキシプロリンの溶液(2.99g、13.89mmol)にN,N−ジイソプロピルエチルアミン(3.7ml、21.24mmol)、4−(ジメチルアミノ)ピリジン(1.74g、14.24mmol)、ジメチルアミン塩酸塩(1.72g、21.09mmol)、及びWSCDI(3.17g、16.68mmol)を加えた。その混合物を室温で30時間撹拌した。その混合物をジクロロメタン(100ml)により希釈し、そして0.3M KHSO4 、飽和重炭酸ナトリウム溶液、及び食塩水により洗浄し、MgSO4により水分を除去し、そして真空中で濃縮して無色の粘性物質を得た。この未精製物を4N HCl/ジオキサン(50ml)中に取り上げ、そして室温で1時間撹拌し、次に真空中で濃縮した。残渣をトルエン及びジエチル・エーテルと共沸して白色の固体を得た;収量0.45g(17%)。
実施例1Bのアミン(0.10g、0.302mmol)を実施例1Cの方法に従って実施例2Aのアミン(0.153g、0.785mmol)と反応させた。その産物をシリカによるフラッシュ・クロマトグラフィー(溶出液 クロロホルム:メタノール:酢酸 95:4:1)により精製した;収量0.95g(66%)。
以下の表に示したさらなる実施例を類似の方法を用いて製造した。
インビトロにおける生物学的性質決定
本発明の化合物は、V2 レセプターに対する選択的アゴニストである。慣例的な放射性リガンド置換アッセイにおいて、前記化合物は全てV2 レセプターに関して10μMより低いKi値を生じる。
Brattleboroラットは、バソプレッシン欠損症のために確立されたモデルである(概説としてFD Grant,「Genetic models of vasopressin deficiency」, Exp. Physiol. 85, 203S-209S, 2000を参照のこと)。その動物は、バソプレッシンを分泌せず、その結果として大量の薄い尿を生じる。本発明の化合物をBrattleboroラットに投与した(0.1〜10mg/kg、経口、メチルセルロースに含み)。尿を1時間ごとに集め、そして量を対象動物と比較した。動物は実験の間を通して飼料及び水を自由摂取させた。代表的な結果を表中に示した。デスモプレッシンに関する結果を比較のために示した。
錠剤のための医薬組成物
活性物質として100mgの実施例1の化合物を含む錠剤を以下のものから製造する:
実施例1の化合物 200.0g
コーンスターチ 71.0g
ヒドロキシプロピルセルロース 18.0g
カルボキシメチルセルロース・カルシウム 13.0g
ステアリン酸マグネシウム 3.0g
ラクトース 195.0g
──────────────────────────────
合計 500.0g
前記物質を混合し、そして次にそれぞれ100mgの実施例1の化合物を含む250mgの錠剤2000個を与える。
Claims (6)
- 1−(2−メチル−4−(2,3,4,5−テトラヒドロ−1−ベンズアゼピン−1−イルカルボニル)ベンジルカルバモイル)−L−プロリン−N,N−ジメチルアミド、又は医薬として許容されるその塩。
- 請求項1に記載の化合物および医薬として許容されるその塩から選ばれる活性物質を含む医薬組成物。
- 多尿症の治療用である、請求項2に記載の医薬組成物。
- 尿失禁の制御用である、請求項2に記載の医薬組成物。
- 排尿遅延用である、請求項2に記載の医薬組成物。
- 血液凝固の異常による出血性疾患の治療用である、請求項2に記載の医薬組成物。
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB0000079.4A GB0000079D0 (en) | 2000-01-05 | 2000-01-05 | Novel antidiuretic agents |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2001550222A Division JP3869723B2 (ja) | 2000-01-05 | 2001-01-04 | バソプレッシン・アゴニストとしての縮合アゼピン |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2006137767A JP2006137767A (ja) | 2006-06-01 |
JP3813629B2 true JP3813629B2 (ja) | 2006-08-23 |
Family
ID=9883168
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2001550222A Expired - Fee Related JP3869723B2 (ja) | 2000-01-05 | 2001-01-04 | バソプレッシン・アゴニストとしての縮合アゼピン |
JP2005366100A Expired - Fee Related JP3813629B2 (ja) | 2000-01-05 | 2005-12-20 | バソプレッシン・アゴニストとしての縮合アゼピン |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2001550222A Expired - Fee Related JP3869723B2 (ja) | 2000-01-05 | 2001-01-04 | バソプレッシン・アゴニストとしての縮合アゼピン |
Country Status (34)
Country | Link |
---|---|
US (3) | US7074781B2 (ja) |
EP (1) | EP1248784B1 (ja) |
JP (2) | JP3869723B2 (ja) |
KR (1) | KR100605466B1 (ja) |
CN (1) | CN1183129C (ja) |
AR (1) | AR035327A1 (ja) |
AT (1) | ATE366730T1 (ja) |
AU (1) | AU777538B2 (ja) |
BR (1) | BR0107414B1 (ja) |
CA (1) | CA2396277C (ja) |
CY (1) | CY1108034T1 (ja) |
CZ (1) | CZ303444B6 (ja) |
DE (1) | DE60129298T2 (ja) |
DK (1) | DK1248784T3 (ja) |
EE (1) | EE200200367A (ja) |
ES (1) | ES2288923T3 (ja) |
GB (1) | GB0000079D0 (ja) |
HK (1) | HK1046910B (ja) |
HR (1) | HRP20020481B1 (ja) |
HU (1) | HU229937B1 (ja) |
IL (1) | IL149528A0 (ja) |
MX (1) | MXPA02006546A (ja) |
MY (1) | MY140467A (ja) |
NO (1) | NO322571B1 (ja) |
NZ (1) | NZ518803A (ja) |
PL (1) | PL211341B1 (ja) |
PT (1) | PT1248784E (ja) |
RU (1) | RU2259367C2 (ja) |
SI (1) | SI1248784T1 (ja) |
SK (1) | SK287005B6 (ja) |
UA (1) | UA73152C2 (ja) |
UY (1) | UY26521A1 (ja) |
WO (1) | WO2001049682A1 (ja) |
ZA (1) | ZA200205180B (ja) |
Families Citing this family (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7138393B2 (en) | 1998-07-24 | 2006-11-21 | Wyeth | Biologically active vasopressin agonist metabolites |
GB0000079D0 (en) * | 2000-01-05 | 2000-02-23 | Ferring Bv | Novel antidiuretic agents |
SI1268418T1 (sl) * | 2000-03-27 | 2006-10-31 | Applied Research Systems | Farmacevtsko aktivni pirolidinski derivati kot bax-inhibitorji |
DE60120940T2 (de) * | 2000-03-27 | 2007-01-25 | Applied Research Systems Ars Holding N.V. | Pyrrolidin-derivate verwendbar als bax-inhibitoren |
GB0015601D0 (en) | 2000-06-26 | 2000-08-16 | Ferring Bv | Novel antidiuretic agents |
GB0115515D0 (en) * | 2001-06-25 | 2001-08-15 | Ferring Bv | Oxytocin agonisys |
GB0210397D0 (en) * | 2002-05-07 | 2002-06-12 | Ferring Bv | Pharmaceutical formulations |
DK1619185T3 (da) | 2003-04-28 | 2011-07-18 | Astellas Pharma Inc | 4,4-difluor-1,2,3,4-tetrahydro-5H-1-benzazepinderivat eller salt deraf |
DK1530967T3 (da) * | 2003-11-13 | 2006-07-03 | Ferring Bv | Blisterpakning og dertil hörende fast dosisform |
EP1813603A1 (en) * | 2004-11-17 | 2007-08-01 | Kissei Pharmaceutical Co., Ltd. | Aromatic amide derivatives, medicinal compositions containing the same, medical uses of both |
EP1867639A1 (en) * | 2005-03-25 | 2007-12-19 | Kissei Pharmaceutical Co., Ltd. | Urea derivative, medicinal composition containing the same, and medicinal use of these |
WO2007052517A1 (ja) * | 2005-10-31 | 2007-05-10 | Sumitomo Chemical Company, Limited | ヒドロキシ-2-ピロリジンカルボキシアミド化合物の製法 |
JP5220611B2 (ja) * | 2006-09-25 | 2013-06-26 | キッセイ薬品工業株式会社 | 1,4−ベンゾジアゼピン誘導体、それを含有する医薬組成物およびそれらの医薬用途 |
WO2008141081A1 (en) * | 2007-05-10 | 2008-11-20 | Amr Technology, Inc. | Aryl- and heteroaryl-substituted tetrahydrobenzo-1,4-diazepines and use thereof to block reuptake of norepinephrine, dopamine, and serotonin |
AU2008283929B2 (en) | 2007-08-06 | 2013-10-10 | Serenity Pharmaceuticals, Llc | Methods and devices for desmopressin drug delivery |
US20100286045A1 (en) | 2008-05-21 | 2010-11-11 | Bjarke Mirner Klein | Methods comprising desmopressin |
US11963995B2 (en) | 2008-05-21 | 2024-04-23 | Ferring B.V. | Methods comprising desmopressin |
EP2712622B1 (en) * | 2008-05-21 | 2016-07-13 | Ferring B.V. | Orodispersible desmopressin for increasing initial period of sleep undisturbed by nocturia |
GB201005623D0 (en) * | 2010-04-01 | 2010-05-19 | Vantia Ltd | New polymorph |
GB201105537D0 (en) | 2011-03-31 | 2011-05-18 | Vantia Ltd | New process |
WO2020154581A1 (en) | 2019-01-24 | 2020-07-30 | Assia Chemical Industries Ltd | Solid state forms of fedovapagon-salicyclic acid co-crystal |
Family Cites Families (34)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3960886A (en) | 1968-07-03 | 1976-06-01 | Sterling Drug Inc. | Substituted N-arylanilines |
CA1047490A (en) | 1973-04-18 | 1979-01-30 | Friedrich Karrer | Ethers |
CH599752A5 (ja) | 1973-04-18 | 1978-05-31 | Ciba Geigy Ag | |
DE2355454A1 (de) | 1973-11-07 | 1976-10-07 | Paul Geisslinger | Lochmaschine |
EP0186817B1 (en) | 1984-12-10 | 1989-08-02 | Nissan Chemical Industries Ltd. | 3(2h)pyridazinone, process for its preparation and anti-allergic agent containing it |
ES2089033T3 (es) | 1989-10-20 | 1996-10-01 | Otsuka Pharma Co Ltd | Compuestos benzoheterociclicos. |
US5753677A (en) | 1989-10-20 | 1998-05-19 | Otsuka Pharmaceutical Co., Ltd. | Benzoheterocyclic compounds |
CA2066104C (en) | 1991-04-19 | 2003-05-27 | Hidenori Ogawa | Benzazepine derivatives as vasopressin antagonists |
JPH05320135A (ja) * | 1992-05-19 | 1993-12-03 | Yamanouchi Pharmaceut Co Ltd | テトラヒドロベンズアゼピン誘導体 |
AU657431B2 (en) | 1992-08-20 | 1995-03-09 | Otsuka Pharmaceutical Co., Ltd. | Benzoheterocyclic compounds as oxytocin and vasopressin antagonists |
TW270927B (ja) * | 1992-10-16 | 1996-02-21 | Otsuka Pharma Co Ltd | |
WO1994012476A1 (en) * | 1992-11-25 | 1994-06-09 | Yamanouchi Pharmaceutical Co., Ltd. | Benzanilide derivative |
AU6219994A (en) * | 1993-03-11 | 1994-09-26 | Yamanouchi Pharmaceutical Co., Ltd. | Compound with vasopressin antagonism |
GB9307527D0 (en) | 1993-04-13 | 1993-06-02 | Fujisawa Pharmaceutical Co | New venzamide derivatives,processes for the preparation thereof and pharmaceutical composition comprising the same |
US5843952A (en) | 1993-07-29 | 1998-12-01 | American Cyanamid Company | Tricyclic benzazepine vasopressin antagonists |
US5968930A (en) | 1993-07-29 | 1999-10-19 | American Cyanamid Company | Tricyclic diazepine vasopressin antagonists and oxytocin antagonists |
US5516774A (en) | 1993-07-29 | 1996-05-14 | American Cyanamid Company | Tricyclic diazepine vasopressin antagonists and oxytocin antagonists |
US5760031A (en) | 1993-07-29 | 1998-06-02 | American Cyanamid Company | Tricyclic benzazepine vasopressin antagonists |
FI1215U1 (fi) * | 1993-12-03 | 1994-02-21 | Valmet Paper Machinery Inc | Anlaeggning i samband med styrningen av en vira |
AU690980B2 (en) * | 1994-05-06 | 1998-05-07 | Koninklijke Philips Electronics N.V. | Microwave transmission system |
ES2199251T3 (es) | 1994-06-15 | 2004-02-16 | Otsuka Pharmaceutical Company, Limited | Derivados benzoheterociclicos utilizables como moduladores de vasopresina o de oxitocina. |
JP2926335B2 (ja) * | 1997-06-13 | 1999-07-28 | 大塚製薬株式会社 | 医薬組成物 |
DE69826677T2 (de) * | 1997-07-30 | 2005-02-10 | Wyeth | Trizyclische Vasopressin-Agonisten |
JP4338305B2 (ja) * | 1997-07-30 | 2009-10-07 | ワイス | 三環系バソプレシンアゴニスト |
EP1119568B1 (en) | 1998-10-09 | 2004-02-18 | Janssen Pharmaceutica N.V. | 4,5-dihydro-isoxazole derivatives and their pharmaceutical use |
GB2355454A (en) | 1999-10-20 | 2001-04-25 | Ferring Bv | Antidiuretic agents |
GB0000079D0 (en) | 2000-01-05 | 2000-02-23 | Ferring Bv | Novel antidiuretic agents |
GB0015601D0 (en) | 2000-06-26 | 2000-08-16 | Ferring Bv | Novel antidiuretic agents |
DE10033337A1 (de) | 2000-07-08 | 2002-01-17 | Boehringer Ingelheim Pharma | Biphenylcarbonsäureamide, ihre Herstellung und ihre Verwendung als Arzneimittel |
GB0120051D0 (en) | 2001-08-16 | 2001-10-10 | Ferring Bv | Oxytocin agonists |
GB0224557D0 (en) | 2002-10-22 | 2002-11-27 | Glaxo Group Ltd | Novel compounds |
EP1449844A1 (en) | 2003-02-14 | 2004-08-25 | Ferring B.V. | benzamide derivatives as oxytocin agonists and vasopressin antagonists |
EP1627876A1 (en) | 2004-08-20 | 2006-02-22 | Ferring B.V. | Heterocyclic condensed compounds useful as antidiuretic agents |
US7341963B2 (en) * | 2005-05-17 | 2008-03-11 | Milliken & Company | Non-woven material with barrier skin |
-
2000
- 2000-01-05 GB GBGB0000079.4A patent/GB0000079D0/en not_active Ceased
-
2001
- 2001-01-04 RU RU2002120798/04A patent/RU2259367C2/ru not_active IP Right Cessation
- 2001-01-04 WO PCT/GB2001/000023 patent/WO2001049682A1/en active IP Right Grant
- 2001-01-04 PT PT01900169T patent/PT1248784E/pt unknown
- 2001-01-04 AU AU23846/01A patent/AU777538B2/en not_active Ceased
- 2001-01-04 DK DK01900169T patent/DK1248784T3/da active
- 2001-01-04 MY MYPI20010027A patent/MY140467A/en unknown
- 2001-01-04 PL PL355808A patent/PL211341B1/pl unknown
- 2001-01-04 US US10/130,749 patent/US7074781B2/en not_active Expired - Lifetime
- 2001-01-04 NZ NZ518803A patent/NZ518803A/xx not_active IP Right Cessation
- 2001-01-04 CN CNB018031323A patent/CN1183129C/zh not_active Expired - Fee Related
- 2001-01-04 AT AT01900169T patent/ATE366730T1/de active
- 2001-01-04 HU HU0203917A patent/HU229937B1/hu not_active IP Right Cessation
- 2001-01-04 BR BRPI0107414-8A patent/BR0107414B1/pt not_active IP Right Cessation
- 2001-01-04 KR KR1020027006382A patent/KR100605466B1/ko active IP Right Grant
- 2001-01-04 EE EEP200200367A patent/EE200200367A/xx unknown
- 2001-01-04 JP JP2001550222A patent/JP3869723B2/ja not_active Expired - Fee Related
- 2001-01-04 SK SK911-2002A patent/SK287005B6/sk not_active IP Right Cessation
- 2001-01-04 UY UY26521A patent/UY26521A1/es not_active IP Right Cessation
- 2001-01-04 DE DE60129298T patent/DE60129298T2/de not_active Expired - Lifetime
- 2001-01-04 CA CA2396277A patent/CA2396277C/en not_active Expired - Lifetime
- 2001-01-04 ES ES01900169T patent/ES2288923T3/es not_active Expired - Lifetime
- 2001-01-04 IL IL14952801A patent/IL149528A0/xx active IP Right Grant
- 2001-01-04 CZ CZ20022305A patent/CZ303444B6/cs not_active IP Right Cessation
- 2001-01-04 AR ARP010100035A patent/AR035327A1/es active IP Right Grant
- 2001-01-04 EP EP01900169A patent/EP1248784B1/en not_active Expired - Lifetime
- 2001-01-04 MX MXPA02006546A patent/MXPA02006546A/es active IP Right Grant
- 2001-01-04 SI SI200130766T patent/SI1248784T1/sl unknown
- 2001-04-01 UA UA2002075517A patent/UA73152C2/uk unknown
-
2002
- 2002-05-31 HR HR20020481A patent/HRP20020481B1/xx not_active IP Right Cessation
- 2002-06-27 NO NO20023137A patent/NO322571B1/no not_active IP Right Cessation
- 2002-06-27 ZA ZA200205180A patent/ZA200205180B/en unknown
- 2002-11-26 HK HK02108525.5A patent/HK1046910B/zh not_active IP Right Cessation
-
2005
- 2005-12-20 JP JP2005366100A patent/JP3813629B2/ja not_active Expired - Fee Related
-
2006
- 2006-03-09 US US11/370,861 patent/US7560454B2/en not_active Expired - Fee Related
-
2007
- 2007-10-04 CY CY20071101261T patent/CY1108034T1/el unknown
-
2008
- 2008-06-23 US US12/213,651 patent/US20080261951A1/en not_active Abandoned
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP3813629B2 (ja) | バソプレッシン・アゴニストとしての縮合アゼピン | |
JP4705105B2 (ja) | 抗利尿薬として有用なヘテロ環式縮合化合物 | |
JP3935071B2 (ja) | 融合アゼピン誘導体および抗利尿剤としての使用 | |
JP2003534331A (ja) | 置換1−アミノアルキルラクタム及びムスカリンレセプターアンタゴニストとしてのそれらの使用 | |
JP4694747B2 (ja) | 二環式バソプレッシン・アゴニスト |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A975 | Report on accelerated examination |
Free format text: JAPANESE INTERMEDIATE CODE: A971005 Effective date: 20060224 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20060307 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20060417 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20060523 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20060531 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 3813629 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
S111 | Request for change of ownership or part of ownership |
Free format text: JAPANESE INTERMEDIATE CODE: R313113 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20090609 Year of fee payment: 3 |
|
R350 | Written notification of registration of transfer |
Free format text: JAPANESE INTERMEDIATE CODE: R350 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20100609 Year of fee payment: 4 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20110609 Year of fee payment: 5 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20110609 Year of fee payment: 5 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20120609 Year of fee payment: 6 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20120609 Year of fee payment: 6 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20130609 Year of fee payment: 7 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
LAPS | Cancellation because of no payment of annual fees |